Jerry Ping

630 total citations
15 papers, 399 citations indexed

About

Jerry Ping is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Jerry Ping has authored 15 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 3 papers in Oncology. Recurrent topics in Jerry Ping's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Jerry Ping is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Jerry Ping collaborates with scholars based in United States, Canada and Italy. Jerry Ping's co-authors include Annick Desjardins, Jan Drappatz, David A. Reardon, Marc C. Chamberlain, Michael D. Prados, Timothy F. Cloughesy, David Schiff, Tom Mikkelsen, John de Groot and Jaymes Holland and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Jerry Ping

15 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerry Ping United States 9 276 249 134 73 65 15 399
Jordina Rovira Spain 8 89 0.3× 227 0.9× 137 1.0× 33 0.5× 52 0.8× 9 310
Hsu-Ping Kuo United States 8 72 0.3× 123 0.5× 186 1.4× 174 2.4× 150 2.3× 10 409
Rishu Agarwal Australia 8 266 1.0× 314 1.3× 239 1.8× 90 1.2× 34 0.5× 18 444
Thomas McFarland United States 12 113 0.4× 227 0.9× 229 1.7× 63 0.9× 83 1.3× 21 401
Yuqin Song China 10 202 0.7× 231 0.9× 206 1.5× 111 1.5× 108 1.7× 65 443
Huiqiang Huang China 8 149 0.5× 297 1.2× 267 2.0× 100 1.4× 90 1.4× 20 460
Jiří Mayer Czechia 7 153 0.6× 309 1.2× 249 1.9× 76 1.0× 25 0.4× 14 386
Nele Fourneau United States 8 145 0.5× 217 0.9× 182 1.4× 143 2.0× 60 0.9× 14 388
Naseer Qayum United Kingdom 11 51 0.2× 174 0.7× 247 1.8× 89 1.2× 26 0.4× 21 358
Laurence Hatteville France 8 46 0.2× 101 0.4× 295 2.2× 70 1.0× 41 0.6× 10 384

Countries citing papers authored by Jerry Ping

Since Specialization
Citations

This map shows the geographic impact of Jerry Ping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Ping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Ping more than expected).

Fields of papers citing papers by Jerry Ping

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Ping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Ping. The network helps show where Jerry Ping may publish in the future.

Co-authorship network of co-authors of Jerry Ping

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Ping. A scholar is included among the top collaborators of Jerry Ping based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Ping. Jerry Ping is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Trotman, Judith, Christian Buske, Alessandra Tedeschi, et al.. (2021). Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clinical Cancer Research. 27(21). 5793–5800. 27 indexed citations
2.
Wilson, Wyndham H., Tycel Phillips, Leslie Popplewell, et al.. (2021). Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Leukemia & lymphoma. 62(9). 2094–2106. 3 indexed citations
3.
Buske, Christian, Alessandra Tedeschi, Judith Trotman, et al.. (2021). Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology. 40(1). 52–62. 64 indexed citations
4.
Fowler, Nathan, Loretta J. Nastoupil, Sven de Vos, et al.. (2020). The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma. British Journal of Haematology. 189(4). 650–660. 20 indexed citations
5.
Buske, Christian, Alessandra Tedeschi, Judith Trotman, et al.. (2020). Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. Blood. 136(Supplement 1). 24–26. 18 indexed citations
6.
Trotman, Judith, Christian Buske, Alessandra Tedeschi, et al.. (2020). Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial. Blood. 136(Supplement 1). 38–39. 5 indexed citations
7.
Goy, André, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.. (2019). Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL. Blood. 134(13). 1024–1036. 88 indexed citations
8.
Ramchandren, Radhakrishnan, Peter Johnson, Nilanjan Ghosh, et al.. (2018). The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. Blood. 132(Supplement 1). 402–402. 3 indexed citations
9.
Wen, Patrick Y., Jan Drappatz, John de Groot, et al.. (2017). Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology. 20(2). 249–258. 85 indexed citations
10.
Cloughesy, Timothy F., Jan Drappatz, John de Groot, et al.. (2017). Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology. 20(2). 259–267. 47 indexed citations
11.
12.
Abou‐Alfa, Ghassan K., Ann‐Lii Cheng, Tim Meyer, et al.. (2015). Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).. Journal of Clinical Oncology. 33(3_suppl). TPS496–TPS496. 13 indexed citations
13.
Wilson, Wyndham H., Leslie Popplewell, Tycel Phillips, et al.. (2015). Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL. Blood. 126(23). 1527–1527. 4 indexed citations
14.
15.
Abou‐Alfa, Ghassan K., Ann‐Lii Cheng, Tim Meyer, et al.. (2014). Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).. Journal of Clinical Oncology. 32(15_suppl). TPS4150–TPS4150. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jordina Rovira Breakdown of academic impact, for papers by Hsu-Ping Kuo Breakdown of academic impact, for papers by Rishu Agarwal Breakdown of academic impact, for papers by Thomas McFarland Breakdown of academic impact, for papers by Yuqin Song Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Jiří Mayer Breakdown of academic impact, for papers by Nele Fourneau Breakdown of academic impact, for papers by Naseer Qayum Breakdown of academic impact, for papers by Laurence Hatteville
Rankless by CCL
2026